FDA approves Ionis drug for rare brain disease; market indifferent

Ionis Pharmaceuticals received FDA approval for a novel drug targeting a rare brain disease. Wall Street's muted reaction suggests the approval was largely anticipated or the commercial potential is limited. The development is significant for patients but has minimal market impact.